We are live on ! Find out more
ANIP icon

ANI Pharmaceuticals
ANIP

121 hedge funds and large institutions have $194M invested in ANI Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 45 increasing their positions, 38 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 38

5% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 20

2% less funds holding

Funds holding: 123 → 121 (-2)

32% less capital invested

Capital invested by funds: $285M → $194M (-$91.5M)

36% less call options, than puts

Call options by funds: $4.58M | Put options by funds: $7.19M

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
121
Holders Change
-2
Holders Change %
-1.63%
% of All Funds
3.22%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
19
Increased
45
Reduced
38
Closed
20
Calls
$4.58M
Puts
$7.19M
Net Calls
-$2.62M
Net Calls Change
-$7.37M

Top Buyers

1
PA
Perceptive Advisors
New York
+$3.43M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.86M
3
CCM
Consonance Capital Management
New York
+$2.78M
4
HVC
Healthcare Value Capital
New Jersey
+$2.54M
5
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$1.81M

Top Sellers

1
SAM
Senzar Asset Management
New York
-$7.8M
2
State Street
State Street
Massachusetts
-$7.06M
3
First Manhattan
First Manhattan
New York
-$6.96M
4
Nomura Holdings
Nomura Holdings
Japan
-$5.58M
5
Deutsche Bank
Deutsche Bank
Germany
-$3.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
51
Dupont Capital Management
Delaware
$468K – – –
Charles Schwab
52
Charles Schwab
California
$455K -$345K -10,181 -43%
Swiss National Bank
53
Swiss National Bank
Switzerland
$449K +$84.8K +2,500 +22%
ACM
54
Ativo Capital Management
Illinois
$438K +$50.9K +1,500 +13%
Tudor Investment Corp
55
Tudor Investment Corp
Connecticut
$418K +$33.2K +980 +9%
MC
56
Menta Capital
California
$406K +$409K +12,047 New
TA
57
Teachers Advisors
New York
$396K – – –
GAM
58
Gotham Asset Management
New York
$393K +$396K +11,688 New
NL
59
NWAM LLC
Washington
$388K -$11.2K -330 -3%
AllianceBernstein
60
AllianceBernstein
Tennessee
$382K – – –
Barclays
61
Barclays
United Kingdom
$378K -$497K -14,654 -56%
SO
62
STRS Ohio
Ohio
$376K – – –
DM
63
Diker Management
New York
$367K +$78K +2,300 +27%
Wells Fargo
64
Wells Fargo
California
$365K +$94.1K +2,773 +34%
AQR Capital Management
65
AQR Capital Management
Connecticut
$356K -$71.9K -2,120 -17%
HighTower Advisors
66
HighTower Advisors
Illinois
$348K +$359K +10,588 New
Comerica Bank
67
Comerica Bank
Texas
$338K +$1.08K +32 +0.4%
RhumbLine Advisers
68
RhumbLine Advisers
Massachusetts
$333K +$3.39K +100 +1%
ProShare Advisors
69
ProShare Advisors
Maryland
$324K -$32.6K -962 -9%
PAM
70
Panagora Asset Management
Massachusetts
$285K -$41.2K -1,216 -13%
Jane Street
71
Jane Street
New York
$283K +$285K +8,395 New
PPA
72
Parametric Portfolio Associates
Washington
$273K +$276K +8,125 New
New York State Common Retirement Fund
73
New York State Common Retirement Fund
New York
$266K – – –
MLICM
74
Metropolitan Life Insurance Company (MetLife)
New York
$255K +$81.7K +2,410 +47%
OC
75
Oppenheimer & Co
New York
$244K -$89.4K -2,636 -27%
1 2
3
4 5

ANIP Hedge Fund Activity: Q1 2016 in Review

121 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q1 2016, worth a combined $194M — down 32% from $285M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ANIP and 19 opened new positions — a net loss of 1 holder — while 38 trimmed existing stakes and 45 added.

The largest buyer was Perceptive Advisors, adding an estimated $3.43M. The largest seller was Senzar Asset Management, cutting an estimated $7.8M.

  • 121 institutional investors held ANI Pharmaceuticals (ANIP) as of Q1 2016, down from 123 in Q4 2015.
  • Funds reported $194M of ANI Pharmaceuticals stock for Q1 2016, down 32% quarter-over-quarter.
  • 19 funds opened new ANI Pharmaceuticals positions in Q1 2016 and 20 closed out, a net change of -1 holder.
  • The largest ANI Pharmaceuticals buyer in Q1 2016 was Perceptive Advisors, an estimated $3.43M added.
  • The largest ANI Pharmaceuticals seller in Q1 2016 was Senzar Asset Management, an estimated $7.8M sold.

Based on aggregated 13F filings for Q1 2016.